Video

Dr. Kelly Stratton discusses 2022 SUO Kidney Cancer Course

Author(s):

Urology Times staff
Conference|SUO Annual Meeting

“It's very interesting to see how this continues to progress as a field,” says Kelly L. Stratton, MD FACS.

Current Time 0:00
Duration 3:09
Loaded: 5.19%
Stream Type LIVE
Remaining Time 3:09
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    In this video, Kelly L. Stratton, MD, FACS, discusses the Kidney Cancer Course held during the 2022 Society of Urologic Oncology Annual Meeting. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.

    Related Videos
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: New strategies emerge for metastatic prostate cancer
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
    5 key trial insights from AUA 2025
    5 key trial insights from AUA 2025
    Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
    Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
    Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
    Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
    Kevin Zorn, MD, on preserving ejaculation with BPH therapies
    Kevin Zorn, MD, on preserving ejaculation with BPH therapies
    Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
    Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
    Alexander Glaser, MD, on real-world outcomes with Aquablation
    Alexander Glaser, MD, on real-world outcomes with Aquablation
    Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
    Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
    Related Content
    Welcome to fabulous Las vegas Nevada sign with blur strip road b | Image Credit: © littlestocker - stock.adobe.com
    May 5th 2025

    AUA 2025 recap: Urologic oncology trials in progress

    Hannah Clarke
    Take a look through some of the notable studies that were spotlighted during this year’s meeting.
    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
    May 4th 2025

    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

    Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
    Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
    TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC
    May 2nd 2025

    TAR-200 elicits high complete response rate in BCG-unresponsive NMIBC

    Hannah Clarke
    Data showed an overall CR rate of 82.4%.
    Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
    April 30th 2025

    Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

    Amy M. Pearlman, MD Ryan Terlecki, MD
    A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
    TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
    April 30th 2025

    TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

    Hannah Clarke
    Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
    Man talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    Published: April 29th 2025 | Updated: April 29th 2025

    Ultra-low PSA responses are more prevalent with darolutamide plus ADT

    Benjamin P. Saylor
    The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.”
    © 2025 MJH Life Sciences

    All rights reserved.